DexCom is a high-quality franchise with a wide economic moat, best-in-class margins, and four consecutive earnings beats, but the stock's current price leaves only 3.3% upside to the analyst target; the thesis favors a patient entry near $64 rather than initiating at current levels where the near-term risk/reward does not clear the minimum bar.
Thesis pillars
- Wide Economic Moat And Compounder Quality→Stable
- Thin Upside At Current Price Level↑Improving
- Four Consecutive Earnings Beats→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026· older than 90 days
DexCom, Inc. (DXCM) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $88.48, but acceptable to hold if already in. Reasons: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers.
DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with products including the G7, G7 15 Day, and the Stelo OTC biosensor sold globally. Revenue comes primarily from CGM system sales through third-party payors... Read more
Hold if already holding. Not a fresh buy at $88.48, but acceptable to hold if already in. Reasons: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Downgraded from BUY WAIT — price $88.48 vs the analyst target $88.34: -0.2% upside; No upside left. Score 6.0/10, moderate confidence.
Passes 6/7 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 98d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated Nov 4, 2026Recent Developments — DexCom, Inc.
Latest news
- NEWS DexCom (DXCM) Stock Price, Chart & Analysis - www.debelegger.nl — www.debelegger.nl Nov 4, 2026 neutral
- NEWS Does Canada CGM Launch Change The Bull Case For DexCom (DXCM)? - Simply Wall St — Simply Wall St Oct 28, 2026 positive
- NEWS Dexcom (DXCM) Receives a Buy from Leerink Partners - The Globe and Mail — The Globe and Mail Oct 28, 2026 positive
- NEWS DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus — GuruFocus Oct 28, 2026 positive
- NEWS What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:39:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCGM systems10-K Item 1A: 'sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future'
- HIGHSuppliersingle- or sole-source suppliers10-K Item 1A: 'our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $88.48, but acceptable to hold if already in. Reasons: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers. Chart setup: Golden cross, above all MAs, RSI 52, MACD bullish. Downgraded from BUY WAIT — price $88.48 vs the analyst target $88.34: -0.2% upside; No upside left. Analyst target $88.34 reached (−0.2%), stop $79.63 (−11.1%), A.R:R -0.0:1. Score 6.0/10, moderate confidence.
Analyst target $88.34 reached (−0.2% from $88.48); no take-profit level is published. Analyst target $88.34 reached (−0.2%), stop $79.63 (−11.1%), A.R:R -0.0:1. Stop-loss: $79.63.
Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source suppliers; Analyst target reached - limited upside remaining.
DexCom, Inc. trades at a P/E of 34.8 (forward 28.2). TrendMatrix value score: 4.1/10. Verdict: Hold.
36 analysts rate DXCM, with a consensus score of 4.3/5. 26 analysts publish price targets averaging $98.
What does DexCom, Inc. do?DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with...
DexCom designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management, with products including the G7, G7 15 Day, and the Stelo OTC biosensor sold globally. Revenue comes primarily from CGM system sales through third-party payors including Medicare, Medicaid, and commercial insurers, with the G7 covered in the majority of states. The G7 15 Day received FDA marketing authorization in April 2025 and is the most accurate CGM cleared by the FDA.